Solifenacin succinate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder, Urinary Incontinence, Urge Incontinence
Trial Timeline
May 1, 2006 → May 1, 2007
NCT ID
NCT00337558About Solifenacin succinate
Solifenacin succinate is a approved stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT00337558. Target conditions include Overactive Bladder, Urinary Incontinence, Urge Incontinence.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189800 | Phase 3 | Completed |
| NCT01981954 | Phase 3 | Completed |
| NCT01565694 | Phase 3 | Completed |
| NCT00909428 | Approved | Completed |
| NCT00337558 | Approved | Completed |
| NCT00463541 | Phase 3 | Completed |
| NCT00454740 | Phase 3 | Completed |
Competing Products
20 competing products in Overactive Bladder